What type of study is this?

This is a In Vitro Study study.

What question did this study set out to answer?

To explore BIRC5 inhibition as a treatment for drug-resistant RAS mutant multiple myeloma.

December 8, 2025BloodOpen Access

BIRC5 inhibition as a novel approach to target RAS mutant and drug-resistant multiple myeloma

View Full Paper

Ask AI

Bookmark

Authors

ZDZachary DavisMerck & Co., Inc., Rahway, NJ, USA (United States)KGKelli GyotokuMayo Clinic in Arizona

Discussion

Member takes

Implication

Experimental findings demonstrate BIRC5 inhibition reduces drug resistance and improves apoptosis in multiple myeloma, suggesting a novel therapeutic approach.

Key Points

To explore BIRC5 inhibition as a treatment for drug-resistant RAS mutant multiple myeloma.
Developed NRasQ61X and KRasG12X mutations in human myeloma cell lines using CRISPR-Cas.
Evaluated 84 FDA-approved oncology drugs for cytotoxicity via a drug combination prediction algorithm and screening platform.
Conducted in vitro assays to assess BIRC5 inhibitors' effects in cell lines with different RAS statuses.
Utilized Mass Cytometry for ex vivo analysis on patient-derived myeloma cells.
BIRC5 inhibitors showed mean IC50 of 4.431 nM in myeloma cells with RAS mutations.
Demonstrated significant synergy when combined with proteasome inhibitors and immunomodulatory drugs.
Mass Cytometry analysis revealed dose-dependent reduction in target gene expressions in myeloma patient samples.

Cite This Study

Davis et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d6c6 https://doi.org/10.1182/blood-2025-5705

View Full Paper

Ask AI

Bookmark

Implication

Experimental findings demonstrate BIRC5 inhibition reduces drug resistance and improves apoptosis in multiple myeloma, suggesting a novel therapeutic approach.

BIRC5 inhibition as a novel approach to target RAS mutant and drug-resistant multiple myeloma

Discussion

Member takes

Implication

Key Points

Cite This Study

BIRC5 inhibition as a novel approach to target RAS mutant and drug-resistant multiple myeloma

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider